The first generic versions of GlaxoSmithKline’s cardiovascular agent Coreg – all 14 of them – have been approved by US regulators. The first generic versions of GlaxoSmithKline’s cardiovascular agent ...

In a joint filing submitted Monday, GSK—the plaintiff in the action—and Teva, in the role of defendant, told the U.S. District Court for the District of Delaware that they have “resolved their ...

Please provide your email address to receive an email when new articles are posted on . Two preparations of carvedilol given to patients with heart failure were found nearly bioequivalent. Researchers ...

The US Food and Drug Administration has approved a label update for GlaxoSmithKline’s Coreg (carvedilol), meaning that the beta-blocker is now available to reduce the risk of suffering a heart attack.

A judge dismissed a $235 million verdict against Teva on Wednesday. (Pixabay) () Prove it, GlaxoSmithKline. So says a judge in the Coreg patent case that last year ended in a $235 million judgment ...

June 21 (Reuters) - A U.S. jury has ordered Teva Pharmaceutical Industries Ltd to pay GlaxoSmithKline Plc more than $235 million for infringing a patent covering its blood pressure drug Coreg, court ...

November 17, 2006 — The US Food and Drug Administration (FDA) has approved safety labeling revisions to advise on the use of carvedilol tablets in diabetic patients; the risk for potentially fatal ...

Carvedilol is a generic drug that’s prescribed for heart failure, high blood pressure, or certain heart problems following a heart attack. It’s available as the brand-name drug Coreg. The cost of ...

Carvedilol (as phosphate) 10mg, 20mg, 40mg, 80mg; ext-rel caps. Coreg CR are supplied as hard gelatin capsules in bottles of 30 in the following strengths: 10 mg – white and green capsule shell ...